Aligos Therapeutics, Inc.
ALGSAligos Therapeutics, Inc. in brief
Aligos Therapeutics, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. Its market value was $43 M on 1 August 2026, which makes it the 21,783rd largest listed company in the world and the 3,921st largest in the USA on this site. In the year to December 2025 it had sales of $2 M and a net loss of $24 M. It employs about 67 people and Lawrence Blatt is its chief executive. Its shares trade under the symbol ALGS (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Aligos Therapeutics, Inc.
Aligos Therapeutics is a Clinical Stage Biopharmaceutical company leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage expertise in liver diseases. The company total assets is 146.5 million USD and total equity is 64.9 million USD as on 2019. The headquarters is in USA.
Aligos Therapeutics, Inc. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 19 October 2020; shares registered for exchange trading on 13 October 2020.
Events of Aligos Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,191 (Jan 2021) · #4,002 (Jan 2022) · #4,951 (Dec 2022) · #4,895 (Jul 2023) · #4,005 (Jan 2024) · #2,167 (Mar 2026) · #3,780 (Aug 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 19.6×
- Price / book
- 0.8×
- Free cash flow yield
- -188.1%
- Net margin
- -1104.6%
- Operating margin
- -4017.4%
- Return on equity
- -45.2%
- Liabilities / assets
- 39.5%
- Revenue growth
- -39.3%
- R&D / revenue
- 3171.2%
- Revenue per employee
- $33 K
- Profit per employee
- $-361 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2M | -39.3% | $-88M | $-24M | -1104.6% |
| Dec 2024 | $4M | -41.7% | $-89M | $-131M | -3634.6% |
| Dec 2023 | $6M | — | $-88M | $-88M | -1416.5% |
| Dec 2022 | — | — | $-98M | $-96M | — |
| Dec 2021 | — | — | $-128M | $-128M | — |
| Dec 2020 | — | — | $-98M | $-109M | — |
| Dec 2019 | — | — | $-54M | $-52M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-83M | — | — | $-2.45 | — |
| Dec 2024 | $-81M | $0M | $-81M | $-20.94 | — |
| Dec 2023 | $-79M | $0M | $-79M | $-34.20 | — |
| Dec 2022 | $-79M | $1M | $-80M | $-2.25 | — |
| Dec 2021 | $-116M | $1M | $-117M | $-3.22 | — |
| Dec 2020 | $-74M | $2M | $-76M | $-10.87 | — |
| Dec 2019 | $-47M | $3M | $-50M | $-26.04 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $3M (+282.4% on a year earlier), net income $-22M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 6, 202610-QQuarterly report · period to Sep 2026
- Nov 6, 20268-KCurrent reportResults of operations
- Sep 15, 20268-KCurrent reportMaterial agreement
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 26, 20268-KCurrent reportDirectors or officers changed · Shareholder vote
- May 7, 202610-QQuarterly report · period to Mar 2026
- May 7, 20268-KCurrent reportResults of operations
- Apr 29, 2026DEF 14AProxy statement
- Apr 21, 20268-KCurrent reportMaterial agreement
- Apr 14, 20268-KCurrent reportOther events
- Mar 5, 202610-KAnnual report · period to Dec 2025
Official filings of Aligos Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $2 M
- Operating income
- $-88 M
- Net income
- $-24 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $89 M
- Total liabilities
- $35 M
- Total equity
- $54 M
As of December-2025
Top 36 institutional investors in Aligos Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Deep Track Capital, LP | 444,110 | 0 (0.00%) | 4.37% | $3 M | Nov 16, 2026 |
| 2 | Sio Capital Management, LLC | 327,237 | 0 (0.00%) | 3.22% | $2 M | Nov 16, 2026 |
| 3 | Parkman Healthcare Partners LLC | 325,537 | New | 3.20% | $2 M | Nov 16, 2026 |
| 4 | Marshall Wace, LLP | 246,579 | 0 (0.00%) | 2.43% | $1 M | Nov 13, 2026 |
| 5 | Schonfeld Strategic Advisors LLC | 181,880 | New | 1.79% | $1 M | Nov 16, 2026 |
| 6 | Woodline Partners LP | 177,362 | 0 (0.00%) | 1.74% | $1 M | Nov 16, 2026 |
| 7 | Vanguard Capital Management LLC | 175,543 | 0 (0.00%) | 1.73% | $1 M | Nov 13, 2026 |
| 8 | Baker Bros. Advisors LP | 83,055 | 0 (0.00%) | 0.82% | $0 M | Nov 16, 2026 |
| 9 | Hhlr Advisors, LTD. | 76,247 | 0 (0.00%) | 0.75% | $0 M | Nov 16, 2026 |
| 10 | D. E. Shaw & Co., Inc. | 71,528 | +5,065 (+7.62%) | 0.70% | $0 M | Nov 16, 2026 |
| 11 | UBS Group AG | 67,298 | +7,312 (+12.19%) | 0.66% | $0 M | Nov 10, 2026 |
| 12 | Geode Capital Management, LLC | 50,310 | +3,137 (+6.65%) | 0.49% | $0 M | Nov 6, 2026 |
| 13 | Prudential Financial Inc | 45,354 | New | 0.45% | $0 M | Nov 16, 2026 |
| 14 | LPL Financial LLC | 38,170 | New | 0.38% | $0 M | Nov 6, 2026 |
| 15 | BlackRock, Inc. | 29,536 | -756 (-2.50%) | 0.29% | $0 M | Nov 13, 2026 |
| 16 | Vanguard Fiduciary Trust Co | 28,612 | 0 (0.00%) | 0.28% | $0 M | Nov 13, 2026 |
| 17 | Two Sigma Investments, LP | 27,522 | New | 0.27% | $0 M | Nov 16, 2026 |
| 18 | Dimensional Fund Advisors LP | 21,044 | 0 (0.00%) | 0.21% | $0 M | Nov 4, 2026 |
| 19 | Gsa Capital Partners LLP | 20,714 | New | 0.20% | $0 M | Nov 16, 2026 |
| 20 | Trexquant Investment LP | 19,395 | +7,056 (+57.18%) | 0.19% | $0 M | Nov 16, 2026 |
| 21 | Verition Fund Management LLC | 18,887 | 0 (0.00%) | 0.19% | $0 M | Nov 13, 2026 |
| 22 | Renaissance Technologies LLC | 15,100 | +4,300 (+39.81%) | 0.15% | $0 M | Nov 12, 2026 |
| 23 | Quadrature Capital Ltd | 13,406 | New | 0.13% | $0 M | Nov 13, 2026 |
| 24 | Citadel Advisors LLC | 11,539 | New | 0.11% | $0 M | Nov 16, 2026 |
| 25 | Rockefeller Capital Management L.P. | 10,276 | +276 (+2.76%) | 0.10% | $0 M | Nov 13, 2026 |
Show all 36: investors 26 to 36
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Federation des caisses Desjardins du Quebec | 3,300 | -1,350 (-29.03%) | 0.03% | $0 M | Nov 16, 2026 |
| 27 | Golden State Wealth Management, LLC | 2,674 | 0 (0.00%) | 0.03% | $0 M | Nov 2, 2026 |
| 28 | Royal Bank Of Canada | 2,231 | +106 (+4.99%) | 0.02% | $0 M | Nov 16, 2026 |
| 29 | Morgan Stanley | 205 | +1 (+0.49%) | 0.00% | $0 M | Nov 13, 2026 |
| 30 | Osaic Holdings, Inc. | 200 | New | 0.00% | $0 M | Nov 12, 2026 |
| 31 | Jpmorgan Chase & Co | 26 | -318 (-92.44%) | 0.00% | $0 M | Nov 12, 2026 |
| 32 | SBI Securities Co., Ltd. | 26 | -100 (-79.37%) | 0.00% | $0 M | Oct 22, 2026 |
| 33 | Tower Research Capital LLC (TRC) | 5 | -354 (-98.61%) | 0.00% | $0 M | Nov 16, 2026 |
| 34 | Elevation Wealth Partners, LLC | 4 | 0 (0.00%) | 0.00% | $0 M | Oct 7, 2026 |
| 35 | BNP Paribas Financial Markets | 3 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 36 | Barclays PLC | 1 | New | 0.00% | $0 M | Nov 6, 2026 |
Mutual funds holding Aligos Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 128,770 | $1 M | 1.3% | <0.01% | +1.4% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 46,773 | $0 M | 0.46% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 24,809 | $0 M | 0.24% | <0.01% | −7.4% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 16,428 | $0 M | 0.16% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 7,553 | $0 M | 0.07% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 8,329 | $0 M | 0.08% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 6,141 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 3,569 | $0 M | 0.04% | <0.01% | +90% | May 31, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 3,200 | $0 M | 0.03% | <0.01% | +321% | May 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 3,573 | $0 M | 0.04% | <0.01% | +6.8% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 2,810 | $0 M | 0.03% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 2,093 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 1,427 | $0 M | 0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 1,855 | $0 M | 0.02% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,090 | $0 M | 0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional US Sustainability Core 1 ETFDimensional Fund Advisors LP | 1,149 | $0 M | 0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust | 332 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 178 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 18 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Aligos Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Carole NuechterleinDirector, 10% owner | Buyindirect | +7.93 M | $0.760 | $6.0 M | 11.03 M | Form 4 |
| filed | James Paul ScopaDirector | Grant or award | +183,083 | $0.760 | $139 K | 183,083 | Form 4 |
| filed | Lawrence BlattChief Executive Officer, Director | Grant or award | +610,277 | $0.760 | $464 K | 1.85 M | Form 4 |
| filed | Thomas WoiwodeDirector | Other10b5-1 plan · indirect | -485,979 | — | — | 1.46 M | Form 4 |
| filed | Thomas WoiwodeDirector | Otherindirect | +9,719 | — | — | 9,719 | Form 4 |
| filed | Thomas WoiwodeDirector | Otherindirect | -9,719 | — | — | 0 | Form 4 |
| filed | Thomas WoiwodeDirector | Otherindirect | +8,383 | — | — | 8,383 | Form 4 |
| filed | Thomas WoiwodeDirector | Otherindirect | -8,383 | — | — | 0 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Aligos Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-25 reverse split ; 1-for-1.11 reverse split
Trading halts
- 2024-11-19 19:32 UTC, code LUDP, resumed 19:37 UTC
- 2024-11-19 19:22 UTC, code LUDP, resumed 19:32 UTC
- 2024-11-19 19:11 UTC, code LUDP, resumed 19:21 UTC
- 2024-11-19 18:59 UTC, code LUDP, resumed 19:04 UTC
- 2024-11-19 18:52 UTC, code LUDP, resumed 18:57 UTC
Fails to deliver
- : 1,384 shares at $4.74
- : 92 shares at $4.82
- : 819 shares at $4.96
- : 1,249 shares at $5.03
- : 216 shares at $4.84
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Aligos Therapeutics, Inc. scorecard#
Passes 2 of the 10 checks that could be worked out: strongest in growth (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth1 of 3
- ✗Revenue grew in the newest year-39.3%Revenue down 39.3% in fiscal 2025.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-2.45 vs -20.94Diluted EPS -2.45 in fiscal 2025 against -20.94 the year before (report's currency).
- ✓Net income higher than five years earlier-$24 M-$24 M in fiscal 2025 against -$109 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$24 MNet income -$24 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-196.9%-196.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities3.9×Current ratio 3.90 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-11.84Z-score -11.84 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year57.8%Diluted shares up 57.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Aligos Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 2.2−39.5%100% | 3.6−41.7%100% | 6.2—100% | 0—— | 0—— | 0—— | — | |
| Research and development | 69−1.2%3177% | 70−3.8%1946% | 73−14.1%1180% | 85−18.3%— | 104+30.4%— | 80+81.4%— | 44—— | |
| General and administrative | 21−9.3%948% | 23−25.4%632% | 31+15.9%495% | 26−7.4%— | 29+59.0%— | 18+79.4%— | 10—— | |
| Operating expenses | 90−3.1%4125% | 93−10.2%2578% | 104−7.0%1674% | 111−16.0%— | 133+35.6%— | 98+81.0%— | 54—— | |
| Operating income | −88—−4025% | −89—−2469% | −88—−1423% | −98—— | −128—— | −98—— | −54—— | |
| Net interest income | 2.2+29.4%101% | 1.7−60.5%47.1% | 4.3+187%69.5% | 1.5—— | — | — | — | |
| Income before tax | −24—−1092% | −131—−3624% | −87—−1403% | −96—— | −128—— | −108—— | −52—— | |
| Income tax | 0.3−5.1%14.4% | 0.3−58.4%9.2% | 0.8+650%12.8% | 0.1−25.9%— | 0.1−11.2%— | 0.2+89.4%— | 0.1—— | |
| Net income attributable to shareholders | −24—−1107% | −131—−3634% | −88—−1416% | −96—— | −128—— | −109—— | −52—— | |
| Earnings per share, basic | -2.45—— | -20.94—— | -34.20r-1.36—— | -2.25—— | -3.22—— | -10.87—— | -26.04—— | |
| Earnings per share, diluted | -2.45—— | -20.94—— | -34.20r-1.36—— | -2.25—— | -3.22—— | -10.87—— | -26.04—— | |
| Shares, weighted average (basic) | 9.9+57.8%— | 6.3+144%— | 2.6r64−94.0%— | 43—— | — | — | — | |
| Shares, weighted average (diluted) | 9.9+57.8%— | 6.3+144%— | 2.6r64−94.0%— | 43+7.1%— | 40+299%— | 10.0+398%— | 2.0—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 18−50.5%20.7% | 37−72.7%52.8% | 136+66.8%89.6% | 81−56.5%55.5% | 187−15.2%79.4% | 220+217%83.1% | 70—47.5% | |
| Short-term investments | 60+199%67.3% | 20—28.5% | — | 44+1035%30.3% | 3.9−83.1%1.7% | 23−51.9%8.7% | 48—32.8% | |
| Other current assets | 4.9−3.6%5.5% | 5.1−4.1%7.3% | 5.3−30.2%3.5% | 7.6−43.8%5.2% | 14+128%5.7% | 5.9+194%2.2% | 2.0—1.4% | |
| Current assets | 83+33.3%93.6% | 62−56.0%88.7% | 141+5.6%93.1% | 134−34.7%91.0% | 204−18.2%86.9% | 250+108%94.2% | 120—82.1% | |
| Property, plant and equipment | 1.9−21.0%2.1% | 2.4−27.5%3.4% | 3.3−32.3%2.2% | 4.8−22.1%3.3% | 6.2−22.8%2.6% | 8.0−6.0%3.0% | 8.5—5.8% | |
| Right-of-use (leased) assets | 3.1−37.8%3.5% | 5.0−24.3%7.1% | 6.6−14.8%4.3% | 7.7−12.4%5.2% | 8.8+27.4%3.7% | 6.9−8.8%2.6% | 7.6—5.2% | |
| Long-term investments | — | — | — | — | 15—6.4% | — | 10—6.8% | |
| Total assets | 89+26.3%100% | 70−53.7%100% | 152+3.3%100% | 147−37.7%100% | 235−11.3%100% | 265+81.1%100% | 147—100% | |
| Accounts payable | 4.0+54.9%4.5% | 2.6+2.1%3.7% | 2.5−46.9%1.7% | 4.7+57.1%3.2% | 3.0−9.0%1.3% | 3.3−12.1%1.2% | 3.8—2.6% | |
| Current liabilities | 21−2.3%24.0% | 22−9.1%31.0% | 24−27.8%15.8% | 33−15.0%22.6% | 39+28.7%16.6% | 30+119%11.4% | 14—9.4% | |
| Lease liabilities (non-current) | 1.5−68.2%1.7% | 4.8−37.5%6.8% | 7.7−16.7%5.1% | 9.2−18.5%6.3% | 11+8.8%4.8% | 10−11.4%3.9% | 12—8.0% | |
| Total liabilities | 35−64.7%39.5% | 99+66.6%141% | 59+38.9%39.2% | 43−15.5%29.2% | 51+11.9%21.5% | 45+54.3%17.1% | 29—20.0% | |
| Retained earnings | −642—−725% | −618—−882% | −487—−321% | −399—−272% | −303—−129% | −175—−65.9% | −66—−45.2% | |
| Shareholders' equity | 54—60.5% | −29−131%−41.3% | 92−11.4%60.8% | 104−43.8%70.8% | 185−16.0%78.5% | 220—82.9% | −65—−44.3% | |
| Total liabilities and equity | 89+26.3%100% | 70−53.7%100% | 152+3.3%100% | 147−37.7%100% | 235−11.3%100% | 265+81.1%100% | 147—100% | |
| Shares outstanding | 6.2+59.9%— | 3.9+28.6%— | 3.0r75−93.0%— | 43+0.5%— | 43+12.0%— | 38r37+871%— | 3.9—— | |
| Cash-flow statement | ||||||||
| Share-based compensation | 5.0−40.3%231% | 8.5−33.2%234% | 13−13.9%204% | 15+9.2%— | 13+352%— | 3.0+296%— | 0.8—— | |
| Cash from operating activities | −83—−3774% | −81—−2236% | −79—−1276% | −79—— | −116—— | −74—— | −47—— | |
| Capital expenditure | — | −0.1—−3.6% | −0.0—−0.3% | −0.9—— | −0.9—— | −2.1—— | −2.8—— | |
| Cash from investing activities | −38—−1730% | −18−141%−506% | 45—727% | −26−970%— | 3.0−90.8%— | 33+382%— | 6.8—— | |
| Shares issued | — | — | 0.0—0.4% | — | — | — | — | |
| Cash from financing activities | 102+28530%4649% | 0.4−99.6%9.8% | 88+53759%1427% | 0.2−99.8%— | 79−59.1%— | 192+125%— | 86—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 5.8+122%100% | 2.8+282%100% | 0−100%— | 2.8+810%100% | 0.2*−72.1%100% | 0.7−40.7%100% | 1.0−9.0%100% | 0.3−55.2%100% | 0.6*−9.8%100% | 1.3—100% | 1.1—100% | 0.7—100% | 0.7*—100% | |
| Research and development | 83+21.7%1430% | 19−21.1%668% | 24+72.1%— | 23+61.0%825% | 17*+6.3%10082% | 24+42.7%3230% | 14−33.8%1448% | 15−11.4%4663% | 16*−28.0%2645% | 17—1342% | 21—1989% | 16—2358% | 22*—3312% | |
| General and administrative | 23+9.1%392% | 5.9+13.6%207% | 5.6+1.1%— | 6.4+26.8%226% | 4.9*−4.2%2926% | 5.2+11.7%697% | 5.6−12.9%576% | 5.1−24.2%1624% | 5.2*−19.6%852% | 4.6—370% | 6.4—601% | 6.7—961% | 6.4*—956% | |
| Operating expenses | 106+18.8%1821% | 25−14.9%875% | 30+51.9%— | 30+52.2%1052% | 22*+3.7%13008% | 29+36.0%3927% | 20−28.9%2024% | 20−15.1%6287% | 21*−26.1%3497% | 21—1712% | 27—2590% | 23—3319% | 29*—4268% | |
| Operating income | −73—−1244% | −22—−773% | −1.9—— | −27—−952% | −22*—−12908% | −28—−3827% | −19—−1924% | −19—−6187% | −21*—−3393% | −20—−1610% | −26—−2490% | −22—−3177% | −26*—−3869% | |
| Net interest income | 1.1−42.1%18.9% | 0.2−50.0%7.1% | 0.2−50.0%— | 0.1−87.5%3.5% | 0.6*+100%355% | 0.4−20.0%54.0% | 0.4+33.3%41.5% | 0.8+33.3%257% | 0.3*−81.3%49.5% | 0.5—40.0% | 0.3—28.3% | 0.6—86.5% | 1.6*—238% | |
| Income before tax | −63—−1077% | −22—−761% | 1.3—— | −23−153%−803% | −20*—−11746% | −31—−4248% | −16−399%−1625% | 43—13868% | −82*—−13552% | −19—−1533% | 5.3—495% | −35—−5020% | −28*—−4155% | |
| Income tax | 3.5+1020%59.8% | 0.3+482%11.5% | 2.8+1419%— | 0.3+637%11.2% | 0.0*+11.1%17.8% | 0.1−38.5%7.6% | 0.2−2.1%19.2% | 0.0+79.2%13.8% | 0.0*—4.5% | 0.1—7.3% | 0.2—17.8% | 0.0—3.5% | −0.0*—−4.5% | |
| Net income attributable to shareholders | −66—−1137% | −22—−772% | −1.5—— | −23−153%−814% | −20*—−11764% | −32—−4256% | −16−413%−1644% | 43—13855% | −82*—−13556% | −19—−1541% | 5.1—477% | −35—−5023% | −28*—−4151% | |
| Earnings per share, basic | — | -2.09—— | -0.14—— | -2.21−143%— | — | -3.04—— | -1.53−289%— | 5.12—— | — | -3.07—— | 0.81r0.03—— | -5.58r-0.22—— | — | |
| Earnings per share, diluted | — | -2.09—— | -0.14—— | -2.21—— | — | -3.04—— | -1.53−289%— | -2.11—— | — | -3.07—— | 0.81r0.03—— | -5.58r-0.22—— | — | |
| Shares, weighted average (basic) | 10+0.9%— | 10+0.9%— | 10+0.8%— | 10+23.7%— | — | 10+65.3%— | 10+65.4%— | 8.4+34.6%— | — | 6.3—— | 6.3r156—— | 6.2r156—— | — | |
| Shares, weighted average (diluted) | 10+0.9%— | 10+0.9%— | 10+0.8%— | 10+19.4%— | — | 10+65.3%— | 10+65.2%— | 8.7+39.4%— | — | 6.3—— | 6.3r157—— | 6.2r156—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 31—65.9% | 31−25.9%65.9% | 30+62.8%45.8% | 30−59.4%46.4% | 18−50.5%20.7% | 42+18.7%38.2% | 19−58.6%13.9% | 74+205%48.9% | 37−72.7%52.8% | 35—40.0% | 45—41.4% | 24—18.9% | 136—89.6% | |
| Short-term investments | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 25−61.1%38.6% | 60+199%67.3% | 57+44.4%52.1% | 104+111%77.4% | 64−27.6%42.5% | 20—28.5% | 40—44.8% | 49—45.5% | 89—69.3% | — | |
| Receivables | — | — | 28—41.9% | — | — | — | — | — | — | — | — | — | — | |
| Other current assets | 2.9—6.2% | 2.9−30.4%6.2% | 3.9−19.7%5.9% | 4.5−13.1%7.0% | 4.9−3.6%5.5% | 4.2−11.7%3.9% | 4.9−1.5%3.6% | 5.2+2.4%3.5% | 5.1−4.1%7.3% | 4.8—5.4% | 5.0—4.6% | 5.1—4.0% | 5.3—3.5% | |
| Current assets | 35—73.5% | 35−66.5%73.5% | 62−51.4%93.7% | 60−58.4%92.4% | 83+33.3%93.6% | 103+29.6%94.2% | 128+28.5%95.0% | 143+21.3%95.0% | 62−56.0%88.7% | 80—90.3% | 100—91.5% | 118—92.3% | 141—93.1% | |
| Property, plant and equipment | 1.2—2.6% | 1.2−40.4%2.6% | 1.3−35.3%2.0% | 1.6−28.2%2.5% | 1.9−21.0%2.1% | 2.0−21.0%1.9% | 2.1−26.2%1.5% | 2.2−27.3%1.5% | 2.4−27.5%3.4% | 2.6—2.9% | 2.8—2.6% | 3.0—2.4% | 3.3—2.2% | |
| Right-of-use (leased) assets | 11—23.4% | 11+208%23.4% | 2.1−48.1%3.2% | 2.6−44.5%4.0% | 3.1−37.8%3.5% | 3.6−33.6%3.3% | 4.1−30.2%3.0% | 4.6−24.6%3.1% | 5.0−24.3%7.1% | 5.4—6.1% | 5.8—5.3% | 6.2—4.8% | 6.6—4.3% | |
| Total assets | 47—100% | 47−57.0%100% | 66−50.8%100% | 65−57.2%100% | 89+26.3%100% | 110+24.1%100% | 135+23.8%100% | 151+17.8%100% | 70−53.7%100% | 88—100% | 109—100% | 128—100% | 152—100% | |
| Accounts payable | 3.2—6.8% | 3.2−30.9%6.8% | 6.4+63.3%9.7% | 7.6+71.3%11.8% | 4.0+54.9%4.5% | 4.7+69.7%4.2% | 3.9−42.3%2.9% | 4.5+56.9%3.0% | 2.6+2.1%3.7% | 2.7—3.1% | 6.8—6.3% | 2.8—2.2% | 2.5—1.7% | |
| Current liabilities | 20—41.5% | 20−10.9%41.5% | 28+39.9%42.7% | 23+23.1%36.1% | 21−2.3%24.0% | 22+4.9%20.0% | 20−14.0%15.0% | 19+0.4%12.6% | 22−9.1%31.0% | 21—23.7% | 24—21.7% | 19—14.8% | 24—15.8% | |
| Lease liabilities (non-current) | 11—22.6% | 11+348%22.6% | 0.3−91.0%0.4% | 0.7−84.5%1.0% | 1.5−68.2%1.7% | 2.4−57.1%2.2% | 3.2−48.8%2.4% | 4.3−39.0%2.8% | 4.8−37.5%6.8% | 5.5—6.3% | 6.3—5.8% | 7.0—5.5% | 7.7—5.1% | |
| Total liabilities | 36—76.0% | 36−5.4%76.0% | 34+4.9%51.9% | 33−4.3%50.8% | 35−64.7%39.5% | 38−1.0%34.6% | 33−21.0%24.4% | 34−49.7%22.7% | 99+66.6%141% | 38—43.3% | 42—38.2% | 68—53.2% | 59—39.2% | |
| Retained earnings | −689—−1459% | −689—−1459% | −667—−1005% | −665—−1030% | −642—−725% | −622—−567% | −591—−439% | −575—−382% | −618—−882% | −536—−606% | −517—−475% | −522—−408% | −487—−321% | |
| Shareholders' equity | 11—24.0% | 11−84.3%24.0% | 32−68.7%48.1% | 32−72.7%49.2% | 54—60.5% | 72+43.4%65.4% | 102+51.5%75.6% | 116+94.7%77.3% | −29−131%−41.3% | 50—56.7% | 67—61.8% | 60—46.8% | 92—60.8% | |
| Total liabilities and equity | 47—100% | 47−57.0%100% | 66−50.8%100% | 65−57.2%100% | 89+26.3%100% | 110+24.1%100% | 135+23.8%100% | 151+17.8%100% | 70−53.7%100% | 88—100% | 109—100% | 128—100% | 152—100% | |
| Shares outstanding | 6.2—— | 6.2+1.5%— | 6.2+1.4%— | 6.2+1.2%— | 6.2+59.9%— | 6.2+85.1%— | 6.2−92.3%— | 6.1−91.9%— | 3.9+28.6%— | 3.3—— | 80—— | 76—— | 3.0r75—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 5.4+2.4%92.9% | 1.3−12.6%45.3% | 1.4+17.5%— | 1.3+37.0%46.4% | 1.5*−14.5%863% | 1.5−28.2%198% | 1.2−43.5%120% | 1.0−63.8%308% | 1.7*−34.0%281% | 2.0—163% | 2.1—194% | 2.6—382% | 2.6*—384% | |
| Cash from operating activities | −68—−1173% | 1.5*—51.3% | −25*—— | −23—−817% | −22*—−12867% | −24*—−3285% | −16*—−1607% | −21—−6723% | −18*—−3037% | −20*—−1608% | −19*—−1837% | −23—−3278% | −23*—−3372% | |
| Cash from investing activities | 58—991% | −0.1*−100%−4.5% | 25*—— | 35—1234% | −2.0*−110%−1196% | 48*+359%6435% | −39*−199%−4085% | −44—−14169% | 20*—3296% | 10*—832% | 40*—3769% | −89—−12773% | −0.0*—−1.0% | |
| Cash from financing activities | 0.3−99.7%4.7% | −0.0*—−0.3% | 0.2*—— | −0.1−100%−2.2% | 0.1*+26.8%72.8% | −0.1*—−7.2% | −0.2*−163%−18.3% | 102—32714% | 0.1*−99.9%16.0% | −0.0*—−0.3% | 0.3*—26.5% | −0.0—−2.7% | 88*—13086% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at Aligos Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Directors and officers 8 · Material agreement 3 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 3 · Shareholder vote 3 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Delisting notice | 8-K | |
| Delisting noticeDirectors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2025 | $105 M | Private placement after listing | $50 to $250 million | 12 | equity, options | SEC |
| Oct 2023 | $92 M | Private placement after listing | $50 to $250 million | 11 | equity, options | SEC |
| Dec 2019 | $85 M | No. 1 | $50 to $250 million | 38 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Aligos Therapeutics, Inc.#
$80 K spent on lobbying the US Congress and federal agencies in 2025, most often on labor issues/antitrust/workplace.
- Labor Issues/Antitrust/Workplace1 report
Lobbying firms hired in 2025
Wilmer Cutler Pickering Hale and Dorr LLP $80 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $140 K | — | 3 |
| 2025 | $80 K | — | 4 |
| 2024 | $0 | — | 4 |
| 2023 | $220 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Aligos Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Aligos Therapeutics, Inc.#
2 labor condition applications certified in fiscal 2026 for 2 positions, at a median wage of $248 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Director of Clinical OperationsNatural Sciences Managers | 2 | $248 K |
Where: San Francisco, CA 1 · South San Francisco, CA 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2026 | 2 | 2 | $248 K | 2 |
| FY2024 | 1 | 1 | $230 K | 1 |
| FY2023 | 1 | 1 | $131 K | 1 |
| FY2022 | 1 | 1 | $131 K | 1 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Aligos Therapeutics, Inc.
How Aligos Therapeutics, Inc. compares in Biotechnology
- Market cap$43 M · higher than 24% of 726
- Revenue$2 M · higher than 31% of 647
- Revenue growth-39.3% · higher than 24% of 438
- Price / sales19.6× · lower than 32% of 339
- Price / book0.8× · lower than 83% of 534
- FCF yield-188.1% · higher than 1% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Aligos Therapeutics, Inc.🇺🇸 | $43 M | — | — | -39.3% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on June-2020
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Aligos Therapeutics, Inc.? Verify and update this profile — free
Show Aligos Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.